Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ron Goeree

Showing results (131-140 of 185) with videos related to

Pageof 19
Sort By:
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|October 7, 2009
Impact of the 1997 Canadian guidelines on the conduct of Canadian-based economic evaluations in the published literatureMorgan E Lim, James M Bowen, Daria O'Reilly, et al.
Health and Quality of Life Outcomes|January 29, 2010
A review of health utilities across conditions common in paediatric and adult populationsJean-Eric Tarride, Natasha Burke, Matthias Bischof, et al.
Vascular Health and Risk Management|February 3, 2009
Effects of study design and trends for EVAR versus OSRRobert Hopkins, James Bowen, Kaitryn Campbell, et al.
Journal of Medical Economics|September 26, 2017
Cost-effectiveness analysis of secukinumab for the treatment of active psoriatic arthritis: a Canadian perspectiveRon Goeree, Sima Chiva-Razavi, Praveen Gunda, et al.
Pharmacoeconomics - Open|November 5, 2022
A Probabilistic Cost-Effectiveness Analysis of Venetoclax and Obinutuzumab as a First-Line Therapy in Chronic Lymphocytic Leukemia in CanadaAnuja Chatterjee, Gijs van de Wetering, Ron Goeree, et al.
Clinical and Experimental Rheumatology|October 10, 2012
The excess burden of rheumatoid arthritis in Ontario, CanadaJean-Eric Tarride, Mahbubul Haq, Hamid R Nakhai-Pour, et al.
International Journal of Technology Assessment in Health Care|April 1, 2009
Economic evaluation of drug-eluting stents compared to bare metal stents using a large prospective study in OntarioRon Goeree, James M Bowen, Gord Blackhouse, et al.
Pharmacoeconomics|March 13, 2010
A review of methods used in long-term cost-effectiveness models of diabetes mellitus treatmentJean-Eric Tarride, Robert Hopkins, Gord Blackhouse, et al.
International Journal of Technology Assessment in Health Care|October 3, 2008
Economic evaluations conducted by Canadian health technology assessment agencies: where do we stand?Jean-Eric Tarride, Catherine Elizabeth McCarron, Morgan Lim, et al.
Cost Effectiveness and Resource Allocation : C/E|June 23, 2010
Cost-utility of Intravenous Immunoglobulin (IVIG) compared with corticosteroids for the treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in CanadaGord Blackhouse, Kathryn Gaebel, Feng Xie, et al.
Pageof 19

Showing results (131-140 of 185) with videos related to

Sort By:
Pageof 19
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|October 7, 2009
Impact of the 1997 Canadian guidelines on the conduct of Canadian-based economic evaluations in the published literatureMorgan E Lim, James M Bowen, Daria O'Reilly, et al.
Health and Quality of Life Outcomes|January 29, 2010
A review of health utilities across conditions common in paediatric and adult populationsJean-Eric Tarride, Natasha Burke, Matthias Bischof, et al.
Vascular Health and Risk Management|February 3, 2009
Effects of study design and trends for EVAR versus OSRRobert Hopkins, James Bowen, Kaitryn Campbell, et al.
Journal of Medical Economics|September 26, 2017
Cost-effectiveness analysis of secukinumab for the treatment of active psoriatic arthritis: a Canadian perspectiveRon Goeree, Sima Chiva-Razavi, Praveen Gunda, et al.
Pharmacoeconomics - Open|November 5, 2022
A Probabilistic Cost-Effectiveness Analysis of Venetoclax and Obinutuzumab as a First-Line Therapy in Chronic Lymphocytic Leukemia in CanadaAnuja Chatterjee, Gijs van de Wetering, Ron Goeree, et al.
Clinical and Experimental Rheumatology|October 10, 2012
The excess burden of rheumatoid arthritis in Ontario, CanadaJean-Eric Tarride, Mahbubul Haq, Hamid R Nakhai-Pour, et al.
International Journal of Technology Assessment in Health Care|April 1, 2009
Economic evaluation of drug-eluting stents compared to bare metal stents using a large prospective study in OntarioRon Goeree, James M Bowen, Gord Blackhouse, et al.
Pharmacoeconomics|March 13, 2010
A review of methods used in long-term cost-effectiveness models of diabetes mellitus treatmentJean-Eric Tarride, Robert Hopkins, Gord Blackhouse, et al.
International Journal of Technology Assessment in Health Care|October 3, 2008
Economic evaluations conducted by Canadian health technology assessment agencies: where do we stand?Jean-Eric Tarride, Catherine Elizabeth McCarron, Morgan Lim, et al.
Cost Effectiveness and Resource Allocation : C/E|June 23, 2010
Cost-utility of Intravenous Immunoglobulin (IVIG) compared with corticosteroids for the treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in CanadaGord Blackhouse, Kathryn Gaebel, Feng Xie, et al.
Pageof 19